Durham, NC
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)Society for Translational Oncology, founded in 2000, is a small nonprofit in the Medical Research sector that reported $477K in total revenue in fiscal year 2024. Net assets of $1.4M represent 36 months of operating reserves.
Global MissionThe Society for Translational Oncology (STO), a 501(c)(3) not-for-profit organization, is dedicated to advancing global oncology and improving patient care by bridging the gap between scientific discovery and clinical application. Our mission is to promote high-quality, equitable healthcare through innovative education and collaborative global efforts. STO empowers healthcare professionals with the knowledge and tools to implement cutting-edge cancer therapies and improve patient outcomes worldwide. Through strategic guidance and global alliances, we work to harmonize cancer clinical trials and regulatory standards, ensuring that life-saving treatments are speedily accessible to all patients with cancer.Continuing Medical Education MissionSTO is committed to providing impactful education to oncology physicians, with the goal of improving the quality and safety of care for patients with cancer. This mission will be fulfilled by offering relevant and effective conti
Oncology experts agree that harmonizing approval processes and clinical trials globally will benefit patients and save lives. The current state of cancer care highlights several major challenges...
Oncology experts agree that harmonizing approval processes and clinical trials globally will benefit patients and save lives. The current state of cancer care highlights several major challenges: lack access to clinical trials and the benefits that accrue from them; disharmony slowing the development and regulatory approval of treatments; and inadequate global infrastructure and collaboration.It is generally accepted that harmonization is important but a targeted and focused effort to achieve this goal is lacking. In response, HARMONY is fostering a global collaborative. With ten million cancer patient deaths annually, it is time to accelerate the goal of building this global network of allies to expedite and coordinate global cancer clinical trials and identify areas of congruence among principal regulatory agencies around the world. Harmonizing will enhance life-changing therapies for cancer patients with success defined as a drug approved anywhere will be available everywhere.
Molecular testing is a foundational element of personalized medicine. Understanding and overcoming challenges in implementing best practice guidelines for molecular testing can support better...
Molecular testing is a foundational element of personalized medicine. Understanding and overcoming challenges in implementing best practice guidelines for molecular testing can support better diagnosis and guide treatment decisions. "Incorporating Molecular Testing to Support Personalized Cancer Care" is a three-part educational program that focuses on the adoption of best practice guidelines and incorporating evidence from an MD Anderson Cancer Network Performance Improvement and Quality Improvement (PI/QI) program (a program of The University of Texas MD Anderson Cancer Center). Piloted at two Cancer Network sites, this PI/QI program aimed to optimize the use of molecular testing in thyroid and lung cancers
STO's initiative, Racial Disparities in Cancer Care, acknowledges the disproportionate burden certain US groups face in cancer rates, screenings, diagnosis, and survival. It strives to heighten...
STO's initiative, Racial Disparities in Cancer Care, acknowledges the disproportionate burden certain US groups face in cancer rates, screenings, diagnosis, and survival. It strives to heighten awareness, identify treatment obstacles, and encourage healthcare professionals to advance change. This initiative, stemming from the "Addressing Racial Disparities in Cancer Care" educational program, aims to prepare healthcare teams to alleviate racial disparities in cancer patient care. Resources from these activities remain available as an educational tool. STO remains committed to continuously developing programs to reduce these disparities and empowering healthcare teams in their ongoing efforts for cancer patients.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $476,537 | $467,002 | +0.0% |
| Expenses | $503,387 | $722,531 | -0.3% |
| Net Income | $-26,850 | $-255,529 | -0.9% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| Ann Murphy PHD | Executive Director | 1.00 |
Officer
Director
|
$0 | $0 | $43,764 |
| Martin J Murphy DMEDSC PHD FASCO | Chairman | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Kenneth B Lee MBA | Treasurer | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| Sean Khozin MD MPH | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Ke Liu MD PHD | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Mace L Rothenberg MD FACP | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Lillian L Siu MD FRCPC FASCO | Director | 1.00 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | No data | No data | No data | No data |
| 2024 | $476,537 | $503,387 | $1,476,634 | $-26,850 |
| 2023 | $467,002 | $722,531 | $1,525,997 | $-255,529 |
| 2022 | $1,410,812 | $885,287 | $1,832,539 | $525,525 |
| 2021 | $1,176,418 | $554,292 | $1,367,988 | $622,126 |
| 2020 | $285,145 | $194,327 | $746,220 | $90,818 |
Compare Society for Translational Oncology with other nonprofits in North Carolina and across the country.